Literature DB >> 1500523

Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps.

T Harmsen1, M C Jongerius, C W van der Zwan, A D Plantinga, C A Kraaijeveld, G A Berbers.   

Abstract

A 50% neutralization enzyme immunoassay (N50-EIA) was compared with an indirect enzyme-linked immunosorbent assay (ELISA) for determining mumps virus antibodies in three consecutive serum samples from 138 children vaccinated with a live mumps vaccine at the age (in years) of 1.5. By the N50-EIA, most (132 of 138) preserum samples did not show neutralizing activity. Eight to 12 weeks after vaccination, 17 of the children were still negative, but only 7 remained so after 2.5 years, resulting in a seroconversion rate of 125 of 132 (95%). Over the same period, the neutralization geometric mean titer rose from 3.6 to 9.9. By an indirect ELISA, 128 of 138 preserum samples were found negative. The early and late postvaccination sera of 8 children were ELISA negative, resulting in a seroconversion rate of 120 of 128 (94%). Only two children remained seronegative by both methods. Seven of the late postvaccination serum samples yielded noncorresponding results, reflecting 95% correlation between both methods. Due to cross-reactivity with parainfluenza viruses, the ELISA proved to be less specific, but on the other hand, it showed a greater sensitivity than the N50-EIA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500523      PMCID: PMC265458          DOI: 10.1128/jcm.30.8.2139-2144.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Enzyme immunoassay of mumps virus in cell culture with peroxidase-labelled virus specific monoclonal antibodies and its application for determination of antibodies.

Authors:  F H van Tiel; C A Kraaijeveld; J Baller; T Harmsen; T A Oosterlaken; H Snippe
Journal:  J Virol Methods       Date:  1988-10       Impact factor: 2.014

2.  Avidity of IgG antibodies against mumps, parainfluenza 2 and Newcastle disease viruses after mumps infection.

Authors:  O P Lehtonen; O H Meurman
Journal:  J Virol Methods       Date:  1986-08       Impact factor: 2.014

3.  Evaluation of enzyme-linked immunosorbent assay (ELISA) for mumps virus antibodies.

Authors:  P O Leinikki; I Shekarchi; N Tzan; D L Madden; J L Sever
Journal:  Proc Soc Exp Biol Med       Date:  1979-03

4.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

5.  Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies.

Authors:  F A Ennis
Journal:  J Infect Dis       Date:  1969-06       Impact factor: 5.226

6.  A plaque neutralization test for determining mumps antibodies.

Authors:  F A Ennis; R D Douglas; G L Stewart; H E Hopps; H M Meyer
Journal:  Proc Soc Exp Biol Med       Date:  1968-12

7.  Epidemiology of mumps in the Netherlands.

Authors:  J H Wagenvoort; M Harmsen; B J Boutahar-Trouw; C A Kraaijeveld; K C Winkler
Journal:  J Hyg (Lond)       Date:  1980-12

8.  Epidemiological standardization of a test for susceptibility to mumps.

Authors:  Z M Shehab; P A Brunell; E Cobb
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

9.  Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation.

Authors:  M R Hilleman; R E Weibel; E B Buynak; J Stokes; J E Whitman
Journal:  N Engl J Med       Date:  1967-02-02       Impact factor: 91.245

10.  Enzyme-linked immunosorbent assay for mumps and parainfluenza type 1 immunoglobulin G and immunoglobulin M antibodies.

Authors:  P Ukkonen; O Väisänen; K Penttinen
Journal:  J Clin Microbiol       Date:  1980-04       Impact factor: 5.948

View more
  13 in total

1.  Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.

Authors:  Gaby P Smits; Pieter G van Gageldonk; Leo M Schouls; Fiona R M van der Klis; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

2.  Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus.

Authors:  J L Backhouse; H F Gidding; P B McIntyre; G L Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

4.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Time-resolved fluoroimmunoassays with monoclonal antibodies for rapid identification of parainfluenza type 4 and mumps viruses.

Authors:  J C Hierholzer; P G Bingham; E Castells; R A Coombs
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice.

Authors:  Corinne Vandermeulen; Lieven Verhoye; Sunil Vaidya; Frédéric Clement; Kevin E Brown; Karel Hoppenbrouwers; Geert Leroux-Roels
Journal:  Immunology       Date:  2010-06-25       Impact factor: 7.397

7.  Differential durability of immune responses to measles and mumps following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland
Journal:  Vaccine       Date:  2019-02-20       Impact factor: 3.641

8.  Neutralization enzyme immunoassay for influenza virus.

Authors:  C A Benne; M Harmsen; J C De Jong; C A Kraaijeveld
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

9.  Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.

Authors:  Sandra Waaijenborg; Susan J M Hahné; Liesbeth Mollema; Gaby P Smits; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Jacco Wallinga
Journal:  J Infect Dis       Date:  2013-05-08       Impact factor: 5.226

10.  Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children.

Authors:  N Weisglas-Kuperus; S Patandin; G A Berbers; T C Sas; P G Mulder; P J Sauer; H Hooijkaas
Journal:  Environ Health Perspect       Date:  2000-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.